Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 2:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 2,103 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Injectable saline Clear all

Conditions: Primary Hyperoxaluria Type 3
Interventions: DCR-PHXC, Sterile Normal Saline (0.9% NaCl); Drug
Lead sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company; Industry
Eligibility: 6 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Boston, Massachusetts • Rochester, Minnesota • New York, New York

Conditions: Obstructed Defecation Syndrome (ODS)
Interventions: Botulinum Toxin-A, Normal Saline; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Lymphoproliferative Disorder, Nasopharyngeal Carcinoma, Leiomyosarcoma, Severe Chronic Active EBV (SCAEBV)
Interventions: LMP specific T cells; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Mixed Dyslipidemia
Interventions: ARO-APOC3, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 15
States / cities: Beverly Hills, California • Northridge, California • Boca Raton, Florida + 11 more

Conditions: 22q13 Deletion Syndrome, Phelan-McDermid Syndrome
Interventions: Insulin-Like Growth Factor-1 (IGF-1), Normal saline; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 5 Years to 12 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Lassa Fever
Interventions: LASSARAB+ aPHAD-SEat 700rU, HDCV Comparator, Normal Saline Placebo, LASSARAB+ aPHAD-SEat 1400rU; Biological · Other
Lead sponsor: Wilbur Chen, MD, MS; Other
Eligibility: 18 Years to 50 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pain, Amputation
Interventions: 10 mL 2% lidocaine, 10 mL preservative free saline; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Alopecia Areata
Interventions: CycloSPORINE Injectable Product, Saline Solution; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Mixed Dyslipidemia
Interventions: ARO-ANG3, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 13
States / cities: Huntington Park, California • Hialeah, Florida • Miami, Florida + 10 more

Conditions: Pancreatic Cancer
Interventions: Pasireotide (SOM230), placebo; Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Spinal Fusion
Interventions: Dexamethasone injection, Saline injection; Drug · Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 10 Years to 18 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hip Dysplasia
Interventions: Ropivacaine, Epinephrine, Ketorolac, NaCl (Saline); Combination Product
Lead sponsor: Michael C Willey; Other
Eligibility: 13 Years to 50 Years
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Hypertension
Interventions: DEFINITY® infusion, Human Recombinant Regular Insulin infusion, Dextrose infusion, Flow mediated vasodilation, Endothelial cell collection, Microvascular perfusion assessment using Definity, Microneurography; Drug · Procedure
Lead sponsor: Wanpen Vongpatanasin; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Rheumatoid Arthritis (RA)
Interventions: Abatacept, Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion), Upadacitinib, Placebo for upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 657 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 44
States / cities: Peoria, Arizona • Sun City, Arizona • Tucson, Arizona + 40 more

Conditions: Deep Venous Thrombosis
Interventions: Desirudin (Iprivask™), Heparin; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Total Knee Arthroplasty, Pain, Postoperative, Adductor Canal Block
Interventions: Multimodal Peripheral Nerve Block Injection, Single Shot Adductor Canal Block, Initial Bolus, Continuous infusion; Procedure · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Skin Cancer Excision Site, Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma
Interventions: Abobotulinumtoxin-A, Control- Saline injection; Drug · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Osteoarthritis (OA) of the Knee
Interventions: Periarticular Injection, Adductor Canal Block, Bupivacaine-Meloxicam; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Grosse Pointe Farms, Michigan

Conditions: Lymphoma, Non-Hodgkin
Interventions: Copanlisib (BAY80-6946), Placebo, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Bendamustine, Prednisone; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 10
States / cities: Chandler, Arizona • West Covina, California • Denver, Colorado + 6 more

Conditions: Myocardial Infarction, Hypercholesterolemia
Interventions: alirocumab, placebo; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Dupuytren's Contracture
Interventions: XIAFLEX / XIAPEX; Biological
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 715 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 25
States / cities: Phoenix, Arizona • Tucson, Arizona • Encinitas, California + 22 more

Conditions: Respiratory Syncytial Virus
Interventions: Placebo, mRNA-1345, Afluria® Quadrivalent, mRNA-1273.214; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 3,317 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 62
States / cities: Birmingham, Alabama • Tucson, Arizona • Garden Grove, California + 51 more

Conditions: Trigeminal Neuralgia
Interventions: Incobotulinumtoxina, Placebo Comparator; Biological · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Epidural Analgesia, Obstetric
Interventions: DepoDur following epidural lidocaine, DepoDur following spinal anesthetic; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Stanford, California

Search by objective public record fields.

Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients

Effects of Botox in Obstructed Defecation Syndrome

Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases

Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia

Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)

DMID 23-0015; Lassa Fever CVD 1000

Sciatic Block in Contralateral Limb Phantom and Residual Limb Pain

Intralesional Cyclosporine for Alopecia Areata

Study of ARO-ANG3 in Adults With Mixed Dyslipidemia

Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess

Spinal Fusions Steroid Study

Can PLIA Reduce Early Post-operative Pain After PAO Surgery?

Neural Mechanism of Aldosterone-induced Insulin Resistance

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery

Single Injection Adductor Canal Block Versus Continuous Adductor Canal Infusion for Total Knee Arthroplasty

Impact of Dysport on PMFF Donor Scar

Novel Extended-Release Bupivacaine Polymer for Sustained Pain Relief Following Total Knee Arthroplasty

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

Alirocumab in Patients With Acute Myocardial Infarction

Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age

Incobotulinum Toxin for the Treatment of Trigeminal Neuralgia

Effects of Epidural Lidocaine on the Pharmacokinetic and Pharmacodynamic Profiles of DepoDur® After Cesarean Delivery